Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 5/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616343 | 0.89 | SFRP1 (0.44) | ALDH1A1GAAHTTSMN1; SMN2 | |
| SCHEMBL4615800 | 0.81 | KMT2A (0.47) | POLB | |
| SCHEMBL4617541 | 0.81 | L3MBTL1 (0.55) | ADRB3ADRB2ADRB1TBXAS1ALDH1A1 | |
| SCHEMBL4618668 | 0.81 | ADRB3 (0.48) | ADRB3ADRB2ADRB1TBXAS1ALDH1A1 | |
| SCHEMBL4617909 | 0.78 | SFRP1 (0.52) | ADRB3ADRB2ADRB1TBXAS1 | |
| SCHEMBL4617064 | 0.77 | SFRP1 (0.61) | POLBALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL4618568 | 0.73 | L3MBTL1 (0.53) | ADRB3ADRB2ADRB1ALDH1A1 | |
| SCHEMBL2841159 | 0.73 | ADRB2 (0.54) | ADRB3ADRB2ADRB1TBXAS1ALDH1A1 | |
| SCHEMBL4618430 | 0.71 | SFRP1 (0.54) | ALDH1A1GAAHTT | |
| SCHEMBL6102808 | 0.71 | ALDH1A1 (0.46) | POLBALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101208299-A | Diarylsulfone sulfonamides and use therof | WYETH CORP (US) | 2008-06-25 | — | — | CN | claimed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| CN-101208299-A | Diarylsulfone sulfonamides and use therof | WYETH CORP (US) | 2008-06-25 | — | — | CN | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | ADRB3 4511/4885ADRB2 4622/4885ADRB1 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.